Pepticom Overview
Pepticom is a biotechnology company using artificial intelligence to streamline peptide drug discovery. Its algorithmic platform combines principles from economic and molecular mechanics to generate a wide scope of active molecules with higher success rates. In this way, Pepticom aims to lower the number of research and development candidates synthesized and tested, with a similar reduction in time and costs compared to traditional lab-based discovery methods. The use of computational technology allows Pepticom to address complex targets unreachable by laboratory methods and to further enhance research and development. The platform utilizes the structure of the target protein to design innovative peptides at atomic resolution. It is also capable of designing several peptides chemistry, including linear, helical, and cyclic peptides, and incorporating D and non-natural amino acids in the process. The company is involved in various successful discovery projects with academic and industry partners and has several molecules in different development stages. In March 2021, Pepticom established a spin-off company, PeptiCov, which will focus on developing treatments for the SARS-CoV-2 virus responsible for the COVID-19 outbreak.
Cumulative Funding Raised Over Time ($)
—Aug 2013
$5.0MAug 2019
$11.6MJan 2025
$14.2MMar 2021
Latest News
growth-positive
Pepticom Closes Series A1 Funding
Pepticom, an AI-driven peptide-based therapeutics company based in Jerusalem, Israel, has successfully raised $6.6 million in a Series A1 funding round. The investment was led by Japan Israel High Tech Ventures 2 LP, with participation from existing investors. The funds will be used to accelerate the development of Pepticoms oral IL-17 inhibitor program, which aims to create improved treatments for autoimmune diseases. Pepticoms innovative approach involves designing fully synthetic, small cyclic peptidomimetic inhibitors that target IL-17A and IL-17F isoforms, achieving key milestones in drug development.
Investment
growth-positive
/PRNewswire/ -- Pepticom, a pioneer in AI-driven peptide-based therapeutics, today announced the successful completion of its Series A1 funding round, securing...
Pepticom, a biotech company specializing in AI-driven peptide-based therapeutics, has successfully completed its Series A1 funding round, securing $6.6 million. The round was led by Japan Israel High Tech Ventures 2 LP, with participation from existing investors. The funding will accelerate the development of Pepticoms oral IL-17 inhibitor program, targeting autoimmune diseases such as psoriasis and psoriatic arthritis. Pepticoms proprietary platform combines machine learning and biochemistry to design peptides with high specificity and stability, offering significant advantages over traditional therapies. The investment validates Pepticoms innovative approach and supports its mission to develop more effective treatments for serious diseases.
Investment
Growth-Positive
Pepticom raises $2.6 million for PeptiCov, spin-off company combatting Covid-19
Pepticom, an AI peptide drug design company, has raised $2.6 million to establish PeptiCov, a company focused on treating the SARS-Cov-2 virus responsible for the Covid-19 outbreak. The funding round was led by the Chartered Group. PeptiCov will use Pepticom’s AI technology to design, discover, and develop novel peptide molecules. Pepticoms AI technology streamlines and accelerates the process of discovering candidates for peptide-based drugs.
Investment
growth-positive
Hebrew University Researchers Submit Proposals to Israel Innovation Authority to Investigate Diagnostics, Treatments, and Cures for Covid-19
Researchers at The Hebrew University of Jerusalem and Yissum start-up companies are exploring methods to combat COVID-19 through AI drug discovery, biochemical detection tools, and diagnostic capabilities. Yissum has submitted research proposals to the Israel Innovation Authority (IIA) and its subsidiaries have adjusted their core technologies to fight the virus. Notable subsidiaries include Pepticom, which is using AI technology to identify inhibitors for Sars Cov2, and Enlivex, which has developed a medication to treat severe symptoms of COVID-19. Yissum is seeking partners to validate and develop these technologies.
PartnersCustomers
growth-positive
Using artificial intelligence to find new drugs faster
Jerusalem-based biotech startup Pepticom has raised $5 million in funding to accelerate its process of peptide-based drug discovery. The company combines expertise in chemistry, artificial intelligence, and big data to screen billions of possible protein and peptide combinations. Pepticom uses artificial intelligence to eliminate molecules that will not be viable, reducing the number of molecules that need to be screened. The company currently generates revenue and works in collaboration with pharmaceutical customers. Pepticoms team may double in size next year with the new investment. The company also works in the field of agriculture, collaborating with Adama on finding new chemicals for crop protection.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $14.2M |
| Last funding | $6.6M |
| Stage | A |
| Rounds | 4 |
| Investors | 3 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | pepticom.com |
Locations
Professor Racah St, Jerusalem, Israel
Photos & Videos
4 item(s)
Pepticom Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsMoleculesTags (14)
bioinformaticsdrug-discoveryimmunologybiotechnologyoncologyanalysis-softwareartificial-intelligenceagriculturepharma-companiespharmaceuticalsmetabolic-diseasebiopharmaceuticalcancerpeptidesGeographic Markets
JapanEuropeChinaUnited StatesPepticom Financials
$14.2M
Total funding
Undisclosed
Capital raised
$6.6M
Last funding
A
Funding stage
4
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
—Aug 2013
$5.0MAug 2019
$11.6MJan 2025
$14.2MMar 2021
Private Equity Funding
A Round
Jan 2025
$6.6M
The Chartered Group (Lead)
Undisclosed Round
Mar 2021
$2.6M
The Chartered Group (Lead)
A Round
Aug 2019
$5M
The Chartered Group, Galia Kut
Seed
Aug 2013
Undisclosed
Rachel Hamburger
Pepticom Lifecycle
Cumulative Funding Raised Over Time
—Aug 2013
$5.0MAug 2019
$11.6MJan 2025
$14.2MMar 2021
All Events
A Round
Jan 2025
$6.6M
The Chartered Group (Lead)
Undisclosed Round
Mar 2021
$2.6M
The Chartered Group (Lead)
A Round
Aug 2019
$5M
The Chartered Group, Galia Kut
Seed
Aug 2013
Undisclosed
Rachel Hamburger
Pepticom News
9 articles
growth-positive
Pepticom Closes Series A1 Funding
Pepticom, an AI-driven peptide-based therapeutics company based in Jerusalem, Israel, has successfully raised $6.6 million in a Series A1 funding round. The investment was led by Japan Israel High Tech Ventures 2 LP, with participation from existing investors. The funds will be used to accelerate the development of Pepticoms oral IL-17 inhibitor program, which aims to create improved treatments for autoimmune diseases. Pepticoms innovative approach involves designing fully synthetic, small cyclic peptidomimetic inhibitors that target IL-17A and IL-17F isoforms, achieving key milestones in drug development.
Investment
growth-positive
/PRNewswire/ -- Pepticom, a pioneer in AI-driven peptide-based therapeutics, today announced the successful completion of its Series A1 funding round, securing...
Pepticom, a biotech company specializing in AI-driven peptide-based therapeutics, has successfully completed its Series A1 funding round, securing $6.6 million. The round was led by Japan Israel High Tech Ventures 2 LP, with participation from existing investors. The funding will accelerate the development of Pepticoms oral IL-17 inhibitor program, targeting autoimmune diseases such as psoriasis and psoriatic arthritis. Pepticoms proprietary platform combines machine learning and biochemistry to design peptides with high specificity and stability, offering significant advantages over traditional therapies. The investment validates Pepticoms innovative approach and supports its mission to develop more effective treatments for serious diseases.
Investment
Growth-Positive
Pepticom raises $2.6 million for PeptiCov, spin-off company combatting Covid-19
Pepticom, an AI peptide drug design company, has raised $2.6 million to establish PeptiCov, a company focused on treating the SARS-Cov-2 virus responsible for the Covid-19 outbreak. The funding round was led by the Chartered Group. PeptiCov will use Pepticom’s AI technology to design, discover, and develop novel peptide molecules. Pepticoms AI technology streamlines and accelerates the process of discovering candidates for peptide-based drugs.
Investment
growth-positive
Hebrew University Researchers Submit Proposals to Israel Innovation Authority to Investigate Diagnostics, Treatments, and Cures for Covid-19
Researchers at The Hebrew University of Jerusalem and Yissum start-up companies are exploring methods to combat COVID-19 through AI drug discovery, biochemical detection tools, and diagnostic capabilities. Yissum has submitted research proposals to the Israel Innovation Authority (IIA) and its subsidiaries have adjusted their core technologies to fight the virus. Notable subsidiaries include Pepticom, which is using AI technology to identify inhibitors for Sars Cov2, and Enlivex, which has developed a medication to treat severe symptoms of COVID-19. Yissum is seeking partners to validate and develop these technologies.
PartnersCustomers
growth-positive
Using artificial intelligence to find new drugs faster
Jerusalem-based biotech startup Pepticom has raised $5 million in funding to accelerate its process of peptide-based drug discovery. The company combines expertise in chemistry, artificial intelligence, and big data to screen billions of possible protein and peptide combinations. Pepticom uses artificial intelligence to eliminate molecules that will not be viable, reducing the number of molecules that need to be screened. The company currently generates revenue and works in collaboration with pharmaceutical customers. Pepticoms team may double in size next year with the new investment. The company also works in the field of agriculture, collaborating with Adama on finding new chemicals for crop protection.
Investment
growth-positive
Israeli AI peptide co Pepticom raises $5m
Pepticom, an Israeli AI peptide drug discovery company, has raised $5 million in a Series A financing round from the Chartered Group. The investment will facilitate the development of new AI models to increase molecular discovery efficacy and reduce risk. Pepticoms AI technology streamlines and accelerates the ability of researchers to discover advanced peptide-based drug candidates, reducing the time and cost of the discovery process. The Chartered Groups investment signals confidence in Pepticoms technology and abilities. Pepticom is a spin-out of Yissum, the tech transfer company of The Hebrew University.
Investment
growth-positive
10 of the coolest biotech companies in Jerusalem
The article discusses the growth of the life-sciences cluster in Jerusalem, Israel. The Jerusalem Development Authoritys BioJerusalem initiative is helping new life-sciences companies set up in the city and attract investors and strategic partners. The article highlights ten small biotech companies in Jerusalem that exemplify the fast-growing ecosystem. The companies are involved in various areas such as stem cell therapies, radiation therapy, drug development, and nanotechnology. The article emphasizes Jerusalems potential to become a global leading community in the field of life sciences.
PartnersInvestmentExpand
growth-positive
Algorithm leads to a dramatic improvement in drug discovery methods
The article discusses the use of a unique computerized algorithm developed by Prof. Amiram Goldblum at the Hebrew University of Jerusalems Institute for Drug Research for drug discovery. The algorithm, called iterative stochastic elimination (ISE), has been successful in reducing drug discovery times from years to weeks. It produces a model for the activity of small molecules on disease-causing proteins, allowing for the screening of millions of molecules and the identification of potential drug candidates. The algorithm has been applied to various biological systems and has led to collaborations with laboratories and pharmaceutical companies worldwide. Pepticom, a company founded in 2011, utilizes the algorithm to design peptide ligands for drug discovery. The algorithm has wide applications beyond drug discovery, including in transportation, aviation, communications, and other complex systems.
PartnersInvestment
growth-positive
Shedding Light into the Darkness of Drug Discovery: Pepticom's AI Peptide Design - JLM-BioCity
Pepticom, a pharmaceutical research company, is using artificial intelligence and machine learning to revolutionize the drug discovery process. Their algorithm designs peptides that interact with specific protein structures, cutting costs and time in drug development. Pepticom has successfully designed a cyclic peptide that activates TLR4 to produce a stronger immunological response to vaccines. They have also suggested a designed peptide for the treatment of glycogen storage disorder type IV. Pepticom is engaged in partnerships with Eli Lilly, Fraunhofer-Gesellschaft, and Adama. The company is located in the Malha Technological Park in Jerusalem.
Partners
Pepticom Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 15 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Pepticom Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 514691880 |
| Crunchbase | pepticom-ltd |
| Last updater | Yotam Maman |
| Updater email | yotamm1988@gmail.com |
| Last update | 2021-03-11T00:00:00.000Z |
| Created | 2014-12-21T00:00:00.000Z |
| Claimed | Yes |